<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>百時美施貴寶公司（NYSE:BMY - 免費報告）- 威廉·布萊爾的投資分析師在 9 月 2 日星期二發佈的報告中上調了對百時美施貴寶 2028 財年每股收益（EPS）的預期。威廉·布萊爾的分析師 M. Phipps 現在預計這家生物製藥公司將發佈 5.67 美元的每股收益，高於他們之前的 5.61 美元預期。市場普遍預計百時美施貴寶當前全年的每股收益為 6.74 美元。</p>
<p>其他一些股票研究分析師也最近對該公司發表了評論。摩根士丹利在 7 月 31 日星期四的研究報告中重申了對百時美施貴寶的 “持有” 評級。大和美國在 8 月 5 日星期二的研究報告中將百時美施貴寶的評級從 “強力買入” 下調至 “持有”。華爾街 Zen 在 6 月 6 日星期五的研究報告中將百時美施貴寶的評級從 “強力買入” 下調至 “買入”。大和資本市場在 8 月 5 日星期二的研究報告中將百時美施貴寶的評級從 “跑贏大盤” 下調至 “中性”，並設定了 42.00 美元的目標價。最後，花旗集團在 8 月 1 日星期五的研究報告中將百時美施貴寶的目標價從 51.00 美元下調至 47.00 美元，並對該股票設定了 “中性” 評級。一位分析師給予該股票 “強力買入” 評級，四位給予 “買入” 評級，十五位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的當前共識評級為 “持有”，共識目標價為 56.38 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p><strong>查看我們關於百時美施貴寶的最新股票報告</strong></p>
<h2>百時美施貴寶價格表現</h2>
<p>NYSE:BMY 在星期四開盤價為 47.48 美元。百時美施貴寶的 52 周低點為 42.96 美元，52 周高點為 63.33 美元。該公司的速動比率為 1.11，流動比率為 1.21，債務與股本比率為 2.54。該股票的市值為 966.4 億美元，市盈率為 19.14，市盈增長比率為 2.41，貝塔值為 0.35。該股票的 50 日移動平均價格為 47.08 美元，200 日移動平均價格為 50.61 美元。</p>
<ul>
<li>百時美施貴寶的疲軟指引可能正在創造機會</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最後一次公佈季度收益結果是在 7 月 31 日星期四。這家生物製藥公司報告本季度每股收益為 1.46 美元，超出市場普遍預期的 1.07 美元，超出 0.39 美元。該公司本季度的收入為 122.7 億美元，而市場普遍預期為 113.2 億美元。百時美施貴寶的股本回報率為 80.04%，淨利潤率為 10.58%。該公司的季度收入較去年同期增長了 0.6%。去年同期，該公司每股收益為 2.07 美元。百時美施貴寶已將其 2025 財年的指引設定為 6.350-6.650 美元每股收益。</p>
<h2>百時美施貴寶宣佈分紅</h2>
<p>該公司最近還披露了季度分紅，分紅於 8 月 1 日星期五支付。7 月 3 日星期四的登記投資者獲得了 0.62 美元的分紅。這代表着每年 2.48 美元的分紅和 5.2% 的收益率。除息日期為 7 月 3 日星期四。百時美施貴寶的派息比率目前為 100.00%。</p>
<h2>百時美施貴寶的內部交易</h2>
<p>在相關消息中，執行副總裁 David V. Elkins 在 9 月 2 日星期二的交易中出售了 56,000 股百時美施貴寶的股票。該股票以平均價格 47.33 美元出售，總價值為 2,650,480.00 美元。出售後，該執行副總裁直接持有公司 167,379 股股票，價值約為 7,922,048.07 美元。此次交易使其持股減少了 25.07%。該交易已在向 SEC 提交的文件中披露，文件可通過此超鏈接訪問。內部人士持有公司股票的 0.07%。</p>
<h2>機構投資者對百時美施貴寶的看法</h2>
<p>幾家機構投資者最近買入和賣出了 BMY 的股票。Brighton Jones LLC 在第四季度將其在百時美施貴寶的持股增加了 33.4%。Brighton Jones LLC 現在擁有 19,728 股這家生物製藥公司的股票，價值 1,116,000 美元，此前在上個季度又購買了 4,935 股。Pictet &amp; Cie Europe AG 在第四季度購買了百時美施貴寶的新頭寸，價值約為 13,094,000 美元。Cary Street Partners Financial LLC 在第四季度購買了百時美施貴寶的新頭寸，價值約為 2,301,000 美元。BOKF NA 在第四季度將其在百時美施貴寶的持股增加了 1.4%。BOKF NA 現在擁有 103,029 股這家生物製藥公司的股票，價值 5,752,000 美元，此前在上個季度又購買了 1,464 股。最後，Centiva Capital LP 在第四季度將其在百時美施貴寶的持股增加了 8.7%。Centiva Capital LP 現在擁有 19,671 股這家生物製藥公司的股票，價值 1,113,000 美元，此前在上個季度又購買了 1,580 股。目前 76.41% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於百時美施貴寶</h2>
<p>（獲取免費報告）</p>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供針對血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者中風/全身栓塞的風險，以及治療深靜脈血栓/DVT/肺栓塞/PE；Opdivo，用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>投資高市盈率成長股</li>
<li>ETF 的回報：3 個可能繼續表現優異的名字</li>
<li>什麼是支撐位？</li>
<li>開學購物達到 400 億美元：3 只值得關注的零售股票</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>谷歌母公司股票在躲避嚴厲反壟斷措施後大幅上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

<p>威廉·布萊爾的投資分析師將百時美施貴寶（NYSE:BMY）2028 財年的每股收益（EPS）預估從 5.61 美元上調至 5.67 美元。該公司當前全年的每股收益共識預估為 6.74 美元。近期，多位分析師調整了對該股票的評級，其中包括一項強烈買入、四項買入、十五項持有和一項賣出。該股票開盤價為 47.48 美元，市值為 966.4 億美元，市盈率為 19.14。百時美施貴寶還宣佈了每季度 0.62 美元的股息，收益率為 5.2%</p>

<ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at William Blair lifted their FY2028 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report released on Tuesday, September 2nd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $5.67 for the year, up from their previous estimate of $5.61. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.</p>
<div class="lb-trans"><p>百時美施貴寶公司（NYSE:BMY - 免費報告）- 威廉·布萊爾的投資分析師在 9 月 2 日星期二發佈的報告中上調了對百時美施貴寶 2028 財年每股收益（EPS）的預期。威廉·布萊爾的分析師 M. Phipps 現在預計這家生物製藥公司將發佈 5.67 美元的每股收益，高於他們之前的 5.61 美元預期。市場普遍預計百時美施貴寶當前全年的每股收益為 6.74 美元。</p>
</div><p>A number of other equities research analysts have also recently commented on the company. Morgan Stanley restated a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America cut Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 5th. Wall Street Zen cut Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, June 6th. Daiwa Capital Markets cut Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Finally, Citigroup dropped their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $56.38.</p>
<div class="lb-trans"><p>其他一些股票研究分析師也最近對該公司發表了評論。摩根士丹利在 7 月 31 日星期四的研究報告中重申了對百時美施貴寶的 “持有” 評級。大和美國在 8 月 5 日星期二的研究報告中將百時美施貴寶的評級從 “強力買入” 下調至 “持有”。華爾街 Zen 在 6 月 6 日星期五的研究報告中將百時美施貴寶的評級從 “強力買入” 下調至 “買入”。大和資本市場在 8 月 5 日星期二的研究報告中將百時美施貴寶的評級從 “跑贏大盤” 下調至 “中性”，並設定了 42.00 美元的目標價。最後，花旗集團在 8 月 1 日星期五的研究報告中將百時美施貴寶的目標價從 51.00 美元下調至 47.00 美元，並對該股票設定了 “中性” 評級。一位分析師給予該股票 “強力買入” 評級，四位給予 “買入” 評級，十五位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的當前共識評級為 “持有”，共識目標價為 56.38 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>查看我們關於百時美施貴寶的最新股票報告</strong></p>
</div><h2>Bristol Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶價格表現</h2>
</div><p>NYSE:BMY opened at $47.48 on Thursday. Bristol Myers Squibb has a 52 week low of $42.96 and a 52 week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market capitalization of $96.64 billion, a PE ratio of 19.14, a price-to-earnings-growth ratio of 2.41 and a beta of 0.35. The stock's 50-day moving average price is $47.08 and its 200-day moving average price is $50.61.</p>
<div class="lb-trans"><p>NYSE:BMY 在星期四開盤價為 47.48 美元。百時美施貴寶的 52 周低點為 42.96 美元，52 周高點為 63.33 美元。該公司的速動比率為 1.11，流動比率為 1.21，債務與股本比率為 2.54。該股票的市值為 966.4 億美元，市盈率為 19.14，市盈增長比率為 2.41，貝塔值為 0.35。該股票的 50 日移動平均價格為 47.08 美元，200 日移動平均價格為 50.61 美元。</p>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百時美施貴寶的疲軟指引可能正在創造機會</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the firm earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最後一次公佈季度收益結果是在 7 月 31 日星期四。這家生物製藥公司報告本季度每股收益為 1.46 美元，超出市場普遍預期的 1.07 美元，超出 0.39 美元。該公司本季度的收入為 122.7 億美元，而市場普遍預期為 113.2 億美元。百時美施貴寶的股本回報率為 80.04%，淨利潤率為 10.58%。該公司的季度收入較去年同期增長了 0.6%。去年同期，該公司每股收益為 2.07 美元。百時美施貴寶已將其 2025 財年的指引設定為 6.350-6.650 美元每股收益。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶宣佈分紅</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，分紅於 8 月 1 日星期五支付。7 月 3 日星期四的登記投資者獲得了 0.62 美元的分紅。這代表着每年 2.48 美元的分紅和 5.2% 的收益率。除息日期為 7 月 3 日星期四。百時美施貴寶的派息比率目前為 100.00%。</p>
</div><h2>Insider Transactions at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百時美施貴寶的內部交易</h2>
</div><p>In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.07% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 David V. Elkins 在 9 月 2 日星期二的交易中出售了 56,000 股百時美施貴寶的股票。該股票以平均價格 47.33 美元出售，總價值為 2,650,480.00 美元。出售後，該執行副總裁直接持有公司 167,379 股股票，價值約為 7,922,048.07 美元。此次交易使其持股減少了 25.07%。該交易已在向 SEC 提交的文件中披露，文件可通過此超鏈接訪問。內部人士持有公司股票的 0.07%。</p>
</div><h2>Institutional Investors Weigh In On Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>機構投資者對百時美施貴寶的看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of BMY. Brighton Jones LLC lifted its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Bank Pictet &amp; Cie Europe AG purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $13,094,000. Cary Street Partners Financial LLC purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $2,301,000. BOKF NA lifted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. BOKF NA now owns 103,029 shares of the biopharmaceutical company's stock worth $5,752,000 after purchasing an additional 1,464 shares in the last quarter. Finally, Centiva Capital LP lifted its stake in Bristol Myers Squibb by 8.7% in the 4th quarter. Centiva Capital LP now owns 19,671 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 1,580 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者最近買入和賣出了 BMY 的股票。Brighton Jones LLC 在第四季度將其在百時美施貴寶的持股增加了 33.4%。Brighton Jones LLC 現在擁有 19,728 股這家生物製藥公司的股票，價值 1,116,000 美元，此前在上個季度又購買了 4,935 股。Pictet &amp; Cie Europe AG 在第四季度購買了百時美施貴寶的新頭寸，價值約為 13,094,000 美元。Cary Street Partners Financial LLC 在第四季度購買了百時美施貴寶的新頭寸，價值約為 2,301,000 美元。BOKF NA 在第四季度將其在百時美施貴寶的持股增加了 1.4%。BOKF NA 現在擁有 103,029 股這家生物製藥公司的股票，價值 5,752,000 美元，此前在上個季度又購買了 1,464 股。最後，Centiva Capital LP 在第四季度將其在百時美施貴寶的持股增加了 8.7%。Centiva Capital LP 現在擁有 19,671 股這家生物製藥公司的股票，價值 1,113,000 美元，此前在上個季度又購買了 1,580 股。目前 76.41% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>關於百時美施貴寶</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供針對血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者中風/全身栓塞的風險，以及治療深靜脈血栓/DVT/肺栓塞/PE；Opdivo，用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Return of the ETFs: 3 Names That Could Keep Outperforming</li>
<li>What is a support level?</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>投資高市盈率成長股</li>
<li>ETF 的回報：3 個可能繼續表現優異的名字</li>
<li>什麼是支撐位？</li>
<li>開學購物達到 400 億美元：3 只值得關注的零售股票</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>谷歌母公司股票在躲避嚴厲反壟斷措施後大幅上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

研究分析師發佈了關於百時美施貴寶 2028 財年收益的預測